My understanding was that the 'AI capable partner'
Post# of 148112
(Total Views: 419)
Posted On: 07/25/2023 5:39:14 PM
My understanding was that the 'AI capable partner' was for the purpose of developing a longer term therapeutic for Leronlimab... (not to find more indications to pursue) In a separate matter, they also are trying to narrow down the specific subgroup of HIV patients that would best benefit from treatments... but that is a separate matter and there was no mention that I remember of AI being involved. (Perhaps the two are combined in the sense that a longer acting therapy would work best for specific subgroups of HIV patients.)
Here is the discussion from the CC:
23:50: Next we will provide an Update on HIV and longer acting development. As mentioned earlier, Dr. Jonah Sacha continues to perform research at OHSU with regards to HIV-PREP, HIV-CURE with a longer acting therapeutic. Dr. Jonah Sacha had previously received an NIH grant which he continues to execute research on. Also as previously mentioned, the company has entered into a partnership with a 3rd party, generative, Artificial Intelligence drug discovery development company. This relationship is to work on the development of a longer acting molecule. We believe working with a company with AI capability will result in an expedited and robust development of this modified longer acting therapeutic for this company. We believe this new, longer acting modified therapeutic will lead to greater potential patient acceptance as it will result in less frequent injections such as monthly, quarterly or even longer instead of the current weekly regimen. Development of the longer acting therapeutic will also allow us to expand our IP portfolio protection, which is important for many reasons, including for partnership opportunities and preserving and increasing the value of our patent portfolio.
25:15: We currently can not publicly name who this partner is due to contractual obligations, however, we do plan to be able to in the future. We are very pleased to have secured this partnership and are excited about what will come out of it.
Here is the discussion from the CC:
23:50: Next we will provide an Update on HIV and longer acting development. As mentioned earlier, Dr. Jonah Sacha continues to perform research at OHSU with regards to HIV-PREP, HIV-CURE with a longer acting therapeutic. Dr. Jonah Sacha had previously received an NIH grant which he continues to execute research on. Also as previously mentioned, the company has entered into a partnership with a 3rd party, generative, Artificial Intelligence drug discovery development company. This relationship is to work on the development of a longer acting molecule. We believe working with a company with AI capability will result in an expedited and robust development of this modified longer acting therapeutic for this company. We believe this new, longer acting modified therapeutic will lead to greater potential patient acceptance as it will result in less frequent injections such as monthly, quarterly or even longer instead of the current weekly regimen. Development of the longer acting therapeutic will also allow us to expand our IP portfolio protection, which is important for many reasons, including for partnership opportunities and preserving and increasing the value of our patent portfolio.
25:15: We currently can not publicly name who this partner is due to contractual obligations, however, we do plan to be able to in the future. We are very pleased to have secured this partnership and are excited about what will come out of it.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼